Routine Blood Tests to Predict Liver Fibrosis in Chronic Hepatitis C

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2012 Feb 29

PMID 22371634

Citations 10

Authors

Yung-Yu Hsieh

Shui-Yi Tung

Kamfai Lee

Cheng-Shyong Wu

Kuo-Liang Wei

Chien-Heng Shen

Te-Sheng Chang

Yi-Hsiung Lin

Affiliations

Soon will be listed here.

Abstract

Aim: To verify the usefulness of FibroQ for predicting fibrosis in patients with chronic hepatitis C, compared with other noninvasive tests.

Methods: This retrospective cohort study included 237 consecutive patients with chronic hepatitis C who had undergone percutaneous liver biopsy before treatment. FibroQ, aspartate aminotransferase (AST)/alanine aminotransferase ratio (AAR), AST to platelet ratio index, cirrhosis discriminant score, age-platelet index (API), Pohl score, FIB-4 index, and Lok's model were calculated and compared.

Results: FibroQ, FIB-4, AAR, API and Lok's model results increased significantly as fibrosis advanced (analysis of variance test: P < 0.001). FibroQ trended to be superior in predicting significant fibrosis score in chronic hepatitis C compared with other noninvasive tests.

Conclusion: FibroQ is a simple and useful test for predicting significant fibrosis in patients with chronic hepatitis C.

Citing Articles

Liver fibrosis stage based on the four factors (FIB-4) score or Forns index in adults with chronic hepatitis C.

Huttman M, Parigi T, Zoncape M, Liguori A, Kalafateli M, Noel-Storr A Cochrane Database Syst Rev. 2024; 8:CD011929.

PMID: 39136280 PMC: 11320661. DOI: 10.1002/14651858.CD011929.pub2.

Pentraxin 3 Detects Clinically Significant Fibrosis in Patients with Chronic Viral Hepatitis C.

Gorka-Dynysiewicz J, Pazgan-Simon M, Zuwala-Jagiello J Biomed Res Int. 2019; 2019:2639248.

PMID: 31061822 PMC: 6466943. DOI: 10.1155/2019/2639248.

Simple non-invasive markers for early diagnosis and determination of the severity of liver diseases.

Gudowska M, Wrona A, Gruszewska E, Panasiuk A, Cylwik B, Swiderska M Clin Exp Hepatol. 2017; 2(4):149-154.

PMID: 28856280 PMC: 5497427. DOI: 10.5114/ceh.2016.63872.

A simple bedside blood test (Fibrofast; FIB-5) is superior to FIB-4 index for the differentiation between non-significant and significant fibrosis in patients with chronic hepatitis C.

Shiha G, Seif S, Eldesoky A, ElBasiony M, Soliman R, Metwally A Hepatol Int. 2017; 11(3):286-291.

PMID: 28425016 DOI: 10.1007/s12072-017-9796-z.

Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.

DAmbrosio R, Degasperi E, Aghemo A, Fraquelli M, Lampertico P, Rumi M PLoS One. 2016; 11(6):e0155967.

PMID: 27304619 PMC: 4909284. DOI: 10.1371/journal.pone.0155967.

References

Cadranel J, Rufat P, Degos F . Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000; 32(3):477-81. DOI: 10.1053/jhep.2000.16602. View

Leroy V, Hilleret M, Sturm N, Trocme C, Renversez J, Faure P . Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol. 2007; 46(5):775-82. DOI: 10.1016/j.jhep.2006.12.013. View

Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet M, Konate A . A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005; 42(6):1373-81. DOI: 10.1002/hep.20935. View

Seeff L . Natural history of hepatitis C. Am J Med. 2000; 107(6B):10S-15S. DOI: 10.1016/s0002-9343(99)00374-5. View

Bedossa P, Dargere D, Paradis V . Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003; 38(6):1449-57. DOI: 10.1016/j.hep.2003.09.022. View

Lok A, Ghany M, Goodman Z, Wright E, Everson G, Sterling R . Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology. 2005; 42(2):282-92. DOI: 10.1002/hep.20772. View

. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology. 1994; 20(1):15-20. View

Forns X, Ampurdanes S, Llovet J, Aponte J, Quinto L, Martinez-Bauer E . Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002; 36(4 Pt 1):986-92. DOI: 10.1053/jhep.2002.36128. View

Lu S, Wang J, Liu S, Hung C, Chen C, Tung H . Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at high-risk for hepatocellular carcinoma. Cancer. 2006; 107(9):2212-22. DOI: 10.1002/cncr.22242. View

10.

Wong J, Bennett W, Koff R, Pauker S . Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA. 1999; 280(24):2088-93. DOI: 10.1001/jama.280.24.2088. View

11.

Bonino F, Oliveri F, Colombatto P, Coco B, MURA D, Realdi G . Treatment of patients with chronic hepatitis C and cirrhosis. J Hepatol. 2000; 31 Suppl 1:197-200. DOI: 10.1016/s0168-8278(99)80401-2. View

12.

Hsieh Y, Tung S, Lee I, Lee K, Shen C, Wei K . FibroQ: an easy and useful noninvasive test for predicting liver fibrosis in patients with chronic viral hepatitis. Chang Gung Med J. 2009; 32(6):614-22. View

13.

Kaserer K, Fiedler R, Steindl P, Muller C, Wrba F, Ferenci P . Liver biopsy is a useful predictor of response to interferon therapy in chronic hepatitis C. Histopathology. 1998; 32(5):454-61. DOI: 10.1046/j.1365-2559.1998.00413.x. View

14.

Rossi E, Adams L, Prins A, Bulsara M, De Boer B, Garas G . Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem. 2003; 49(3):450-4. DOI: 10.1373/49.3.450. View

15.

Williams A, Hoofnagle J . Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology. 1988; 95(3):734-9. DOI: 10.1016/s0016-5085(88)80022-2. View

16.

Hanley J, McNeil B . A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983; 148(3):839-43. DOI: 10.1148/radiology.148.3.6878708. View

17.

Maharaj B, Maharaj R, Leary W, Cooppan R, Naran A, Pirie D . Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 1986; 1(8480):523-5. DOI: 10.1016/s0140-6736(86)90883-4. View

18.

Colloredo G, Guido M, Sonzogni A, Leandro G . Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol. 2003; 39(2):239-44. DOI: 10.1016/s0168-8278(03)00191-0. View

19.

Regev A, Berho M, Jeffers L, Milikowski C, Molina E, Pyrsopoulos N . Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002; 97(10):2614-8. DOI: 10.1111/j.1572-0241.2002.06038.x. View

20.

Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T . Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol. 2001; 96(11):3142-6. DOI: 10.1111/j.1572-0241.2001.05268.x. View